UNSPSC 51162735: Naphazoline nitrate

This classification denotes an alpha-adrenergic agonist with the molecular formula C14H14N2.HNO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier SC99GR1T5S, chemically known as 2-imidazoline, 2-(1-naphthylmethyl)-, mononitrate but more generally known as naphazoline nitrate, which bears US NIH Compound Identifier 21225. European Medicines Agency schedules Naphazoline nitrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03390MIG.

Most nations, for tariff and trade purposes, schedule naphazoline nitrate under HS 29332990 and SITC 51573. Naphazoline Nitrate bears US NLM identifiers UMLS ID C0770988 and NCI Concept Code C98243. As of Q4 2014, NAPHAZOLINE NITRATE remains US FDA's Preferred Term for this commodity. SMILES: C1CCC2C(C1)CCCC2CC3=NCCN3.[N+](=O)(O)[O-].

UNSPSC 51162735 Naphazoline nitrate is a Commodity code that encompasses pharmaceutical products state and local governments procure for medical and emergency-response use. Recent solicitations show naphazoline and related pharmaceutical products being requested as components of broader parenteral and emergency-care procurement packages by correctional facilities and county health agencies. State and local buyers use this code to source pharmaceutical inventory for healthcare delivery to incarcerated populations and community health initiatives, often bundled with related medical products and services rather than as standalone items.

The Washington State Department of Corrections and Seminole County, Florida are the identified recent issuing bodies. The DOC RFQ (RFQQK13020, due October 7, 2026) solicits parenteral products, services, and equipment including intravenous solutions for eight correctional facilities across three regions, with naphazoline nitrate likely included in the broader pharmaceutical inventory; the contract anticipates multiple award selections of up to three bidders per region, with initial term through June 30, 2030 and fixed pricing for two years. Seminole County's IFB (IFB60459723LAS, posted June 30, 2026) requests 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries, suggesting demand for emergency-response pharmaceuticals in county health programs. Activity to date shows issuing bodies span correctional systems and municipal health agencies in Washington and Florida; the code shows limited recent visibility in state and local procurement databases, indicating either narrow application or tagging inconsistency with actual pharmaceutical procurement activity.